6:2 Cl-PFAES 是一种口服有效的 Perfluorooctane sulfonate 替代物,可显著抑制斑马鱼生长并诱发生殖毒性,降低雄性 BALB/c 小鼠的附睾和睾丸相对重量,并可用于镀铬行业。
产品编号: MS-B45517 纯度: 99.98% CAS No.: 73606-19-6 分子式: C8ClF16KO4S 分子量: 570.67
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
250mg
询价
3-5 天
500mg
询价
询价
1g
询价
询价

产品描述

6:2 Cl-PFAES 是一种口服有效的 Perfluorooctane sulfonate 替代物,可显著抑制斑马鱼生长并诱发生殖毒性,降低雄性 BALB/c 小鼠的附睾和睾丸相对重量,并可用于镀铬行业。

生物实验数据

生物活性 6:2 Cl-PFAES is an orally effective Perfluorooctane sulfonate substitute that significantly inhibits zebrafish growth and induces reproductive toxicity, reduces the relative weights of the epididymis and testis in male BALB/c mice, and can be used in the chrome plating industry.
体内研究
(In Vivo)

6:2 Cl-PFAES (F-53B) (经水体持续暴露,180 天,5-500 μg/L) 可诱导 F0 代斑马鱼产生生殖毒性,包括生长受损、性腺功能下降、性激素水平改变及 HPG 轴基因表达紊乱;还可通过母体传递对 F1 和 F2 代子代造成多世代发育与生殖损伤,在低至 5 μg/L 的剂量下即可观察到显著效应。
6:2 Cl-PFAES (0.04-1.0 mg/kg/d;口服;每日;连续 56 天) 在 1.0 mg/kg/d 的最高剂量下,可使成年雄性 BALB/c 小鼠的相对睾丸重量降低 8%,附睾绝对重量和相对重量分别降低 14% 和 16%,但不会改变其生殖激素水平、组织病理学特征、精子质量、生育能力或睾丸基因/蛋白表达。

Animal Model: Tüebingen (5-month-old sexually mature adults, F0 generation; F1 and F2 generations derived from F0 fish)
Dosage: 5 μg/L; 50 μg/L; 500 μg/L
Administration: waterborne; continuous; 180 days (F0 generation); no direct exposure (F1 and F2 generations, maternal transfer)
Result: Significantly reduced body weight, body length, condition factor, and gonadosomatic index (GSI) in both sexes of F0 zebrafish at 5 and 50 μg/L.
Caused 85% mortality in male F0 zebrafish at 500 μg/L, with surviving fish unable to reproduce.
Reduced egg production per female F0 zebrafish at 5 and 50 μg/L.
Significantly increased serum testosterone, estradiol, and vitellogenin levels in male F0 zebrafish at 5 μg/L, and increased serum testosterone levels in female F0 zebrafish at 5 and 50 μg/L, altering T/E2 ratios.
Induced gonadal histological changes in F0 zebrafish at 5 and 50 μg/L: testes developed lacunae and reduced mature spermatocytes; ovaries had reduced mature oocytes.
Altered transcriptional levels of multiple hypothalamic-pituitary-gonadal (HPG) axis genes in F0 zebrafish at 5 and 50 μg/L, with down-regulation of brain genes (e.g., gnrh3, fshb, lhb) in most cases, and altered gonadal steroidogenic gene expression (e.g., increased cyp19a in testes, increased hmgra, star, cyp17 in ovaries).
Induced 1576 differentially expressed genes in testes of F0 zebrafish at 50 μg/L, enriched in pathways related to spermatogenesis (e.g., cytokine-cytokine receptor interaction, lysosome, focal adhesion).
Significantly reduced body weight, body length, and female GSI in F1 offspring from 5 μg/L exposed F0 parents; reduced serum testosterone levels in male F1 offspring.
Increased embryo malformation rate to 9.0% and 15.0% at 120 hpf, and increased mortality rates at 120 hpf in F1 offspring from 5 and 50 μg/L exposed F0 parents; F1 offspring from 50 μg/L exposed F0 parents died before 15 dpf.
Detected target reagent in adult blood (0.31 ng/mL males, 0.37 ng/mL females) and gonads (0.10 ng/mg males, 0.12 ng/mg females), and reduced mature oocytes in ovaries of F1 offspring from 5 μg/L exposed F0 parents.
Increased embryo malformation rate to 5.0% at 120 hpf and reduced survival rate in F2 offspring from 5 μg/L exposed F0 parents.
Animal Model: BALB/c (male, 6-8 weeks old)
Dosage: 0.04 mg/kg/d; 0.2 mg/kg/d; 1.0 mg/kg/d
Administration: p.o.; daily; 56 days
Result: Decreased relative testis weight by 8% in the 1.0 mg/kg/d group compared to control.
Decreased absolute epididymis weight by 14% in the 1.0 mg/kg/d group compared to control.
Decreased relative epididymis weight by 16% in the 1.0 mg/kg/d group compared to control.
Reached serum 6:2 Cl-PFAES levels of 5.89 μg/mL (0.04 mg/kg/d), 18.89 μg/mL (0.2 mg/kg/d), and 58.33 μg/mL (1.0 mg/kg/d).
Reached testis 6:2 Cl-PFAES levels of 5.6 μg/g (0.04 mg/kg/d), 14.4 μg/g (0.2 mg/kg/d), and 49.93 μg/g (1.0 mg/kg/d), representing 5.9×103-, 1.5×104-, and 5.3×104-fold increases over control (0.95 ng/g).
Reached epididymis 6:2 Cl-PFAES levels of 1.69 μg/g (0.04 mg/kg/d), 2.68 μg/g (0.2 mg/kg/d), and 9.64 μg/g (1.0 mg/kg/d), representing 26.1-, 41.4-, and 149-fold increases over control (0.065 μg/g).
Showed no significant changes across all doses in serum or testicular testosterone, estradiol, follicle-stimulating hormone, or luteinizing hormone levels; testis/epididymis histopathology; sperm count; fertility metrics (mating index, litter size, pup birth/weaning weight, pup sex ratio); testicular gene expression profiles; or testicular levels of steroidogenic proteins (STAR, CYP11A1, CYP17A1, 3β-HSD) or cell junction proteins (occludin, β-catenin, connexin 43).
性状 固体
颜色 Colorless to off-white

化学信息

分子量 570.67
分子式 C8ClF16KO4S
CAS No. 73606-19-6

储存&溶解度

储存方式

Store at room temperature, keep dry and cool

In solvent -80°C 1 year
-20°C 6 months
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (175.23 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.7523 mL8.7616 mL17.5233 mL43.8082 mL
5 mM0.3505 mL1.7523 mL3.5047 mL8.7616 mL
10 mM0.1752 mL0.8762 mL1.7523 mL4.3808 mL
15 mM0.1168 mL0.5841 mL1.1682 mL2.9205 mL
20 mM0.0876 mL0.4381 mL0.8762 mL2.1904 mL
25 mM0.0701 mL0.3505 mL0.7009 mL1.7523 mL
30 mM0.0584 mL0.2921 mL0.5841 mL1.4603 mL
40 mM0.0438 mL0.2190 mL0.4381 mL1.0952 mL
50 mM0.0350 mL0.1752 mL0.3505 mL0.8762 mL
60 mM0.0292 mL0.1460 mL0.2921 mL0.7301 mL
80 mM0.0219 mL0.1095 mL0.2190 mL0.5476 mL
100 mM0.0175 mL0.0876 mL0.1752 mL0.4381 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础